Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022

  • ID: 4333048
  • Report
  • 198 Pages
  • Markets and Markets
1 of 5
The Global Preimplantation Genetic Testing Market is Expected to Reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%

FEATURED COMPANIES

  • ABBott Laboratories
  • Genea Limited
  • Illumina, Inc.
  • Natera, Inc.
  • Perkinelmer, Inc.
  • Scigene
  • MORE

“Preimplantation genetic testing market projected to grow at a CAGR of 10.0%”

The global preimplantation genetic testing market is expected to reach USD 541.8 million by 2022 from USD 336.4 million in 2017, at a CAGR of 10.0%. Growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are some of the key factors driving the growth of this market. However, the high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the factors restraining the growth of this market

“Next-generation Sequencing is expected to grow at the highest CAGR during 2017 to 2022”

By technology, the preimplantation genetic testing market covers next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP). The NGS segment is expected to grow at the highest CAGR during 2017 to 2022, owing to benefits like reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments, and reduction in human errors due to increased automation.

“The maternity centers & fertility clinics to dominate the global preimplantation genetic testing market during the forecast period”

On the basis of end users, the preimplantation genetic testing market is segmented into maternity centers & fertility clinics; hospitals, diagnostic labs, and service providers; and research laboratories & academic institutes. The maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market in 2016 owing to the high success rate of treatments at fertility centers.

“APAC is projected to witness the highest growth during the forecast period “

While North America accounted for the largest share of the market in 2016, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022. This is owing to the focus of key market players in this region, growing number of ART & IVF procedures in the region, continuous decline in average fertility rate, government initiatives for expansion and modernization of healthcare infrastructure across respective countries, and growing medical tourism across APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:

  • By Company Type - Tier 1 -50%, Tier 2 -33% and Tier 3 -17%
  • By Designation - C level - 17%, Director level - 50%, Others - 33%
  • By Region - North America - 34%, Europe - 26%, APAC - 35%, RoW - 5%

The major players in the market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

Research Coverage

This report studies the preimplantation genetic testing market based on technology, product & service, procedure type, application, and end user. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:

This research focuses on various levels of analysis-industry trends, vendor dive analysis of 25 market players, and company profiles of top 15 market players-which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preimplantation genetic testing market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on business strategies adopted by the major players in the preimplantation genetic testing market. The report analyzes the preimplantation genetic testing market based on technology, product & service, procedure type, application, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the preimplantation genetic testing market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preimplantation genetic testing products across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the preimplantation genetic testing  market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the preimplantation genetic testing market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ABBott Laboratories
  • Genea Limited
  • Illumina, Inc.
  • Natera, Inc.
  • Perkinelmer, Inc.
  • Scigene
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency Used
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Methodology Steps
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Breakdown of Primaries
2.1.2.2 Key Data From Primary Sources
2.2 Market Size Estimation
2.2.1 Research Methodology: Bottom-Up Approach
2.2.2 Research Methodology: Top-Down Approach
2.3 Research Design
2.4 Data Validation and Triangulation
2.4.1 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Preimplantation Genetic Diagnosis and Screening: Market Overview
4.2 Geographic Analysis: Preimplantation Genetic Diagnosis and Screening Market, By Technology (2016)
4.3 Preimplantation Genetic Testing Market , By Application, 2017 vs 2022
4.4 Preimplantation Genetic Testing Market , By Product & Service (2017 vs 2022)
4.5 Geographical Snapshot of the Preimplantation Genetic Diagnosis and Screening Market

5 Preimplantation Genetic Testing Market: Overview
5.1 Introduction
5.2 Market Evolution: Preimplantation Genetic Diagnosis and Screening Technologies
5.3 Market Dynamics
5.3.1 Major Market Drivers
5.3.1.1 Declining Fertility Rates Worldwide
5.3.1.2 Increasing Public-Private Investments in the Field of Preimplantation Genetic Testing
5.3.1.3 Rising Number of Fertility Clinics Worldwide
5.3.1.4 Technological Advancements in the Field of Genetic Analysis
5.3.1.5 High Risk of Chromosomal Abnormalities With Advancing Maternal Age
5.3.2 Major Market Restraints
5.3.2.1 High Procedural Cost Associated With Preimplantation Genetic Testing
5.3.2.2 Unfavorable Government Regulations
5.3.3 Major Market Opportunities
5.3.3.1 Growth Opportunities in Emerging Markets
5.3.3.1.1 Improving Healthcare Infrastructure
5.3.3.1.2 Growing Medical Tourism
5.3.3.1.3 Growth Initiatives By Key Market Players
5.3.3.2 Growing Awareness on Assisted Reproduction Techniques
5.3.4 Major Market Challenges
5.3.4.1 Socioethical Concerns Regarding Preimplantation Genetic Testing
5.3.4.2 Procedural Limitations of Preimplantation Genetic Testing With Advancing Age

6 Industry Insights
6.1 Value Chain Analysis
6.2 Porter’s Five Forces Analysis
6.3 Regulatory Scenario

7 Preimplantation Genetic Diagnosis and Screening Market, By Procedure Type
7.1 Introduction
7.2 Preimplantation Genetic Screening
7.3 Preimplantation Genetic Diagnosis

8 Preimplantation Genetic Diagnosis and Screening Market, By Technology
8.1 Introduction
8.2 Next-Generation Sequencing
8.3 Polymerase Chain Reaction
8.4 Fluorescence in Situ Hybridization
8.5 Comparative Genomic Hybridization
8.6 Single-Nucleotide Polymorphism

9 Preimplantation Genetic Diagnosis and Screening Market, By Product and Service
9.1 Introduction
9.2 Reagents and Consumables
9.3 Instruments
9.4 Software and Services

10 Preimplantation Genetic Diagnosis and Screening Market, By Application
10.1 Introduction
10.2 Aneuploidy
10.3 Structural Chromosomal Abnormalities
10.3.1 Translocations
10.3.2 Deletions
10.3.3 Duplications
10.3.4 Inversions
10.4 Single Gene Disorders
10.5 X-Linked Disorders
10.6 HLA Typing
10.7 Gender Identification

11 Preimplantation Genetic Diagnosis and Screening Market, By End User
11.1 Introduction
11.2 Maternity Centers & Fertility Clinics
11.3 Hospitals, Diagnostic Labs, and Service Providers
11.4 Research Laboratories & Academic Institutes

12 Preimplantation Genetic Diagnosis and Screening Market, By Region
12.1 Introduction
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Rest of Asia-Pacific
12.5 Rest of the World

13 Preimplantation Genetic Testing Market: Competitive Landscape
13.1 Introduction
13.2 Leading Players in the Preimplantation Genetic Testing Market
13.3 Competitive Situation and Trends
13.3.1 Agreements, Collaborations, and Partnerships
13.3.2 Product Launches and Approvals
13.3.3 Acquisitions
13.3.4 Expansions
13.3.5 Other Developments
13.4 Global Preimplantation Genetic Diagnosis and Screening Competitive Leadership Mapping, 2017
13.4.1 Visionary Leaders
13.4.2 Innovators
13.4.3 Dynamic Differentiators
13.4.4 Emerging Companies
13.5 Competitive Leadership Mapping
13.5.1 Strength of Product Portfolio (For 25 Players)
13.5.2 Business Strategy Excellence (For 25 Players)

*Top 25 Companies Analysed for This Study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Perkinelmer, Inc. (U.S.), Coopersurgical, Inc. (U.S.), ABBott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), Scigene (U.S.), Beijing Genomics Institute (China), Good Start Genetics (U.S.), Invicta Genetics (Poland), Combimatrix Corporation (U.S.), Genea Limited (Australia), Progenesis (U.S.), Arrayit Corporation (U.S.), Macrogen, Inc. (South Korea), Elucigene Diagnostics (U.K.), Reproductive Health Science Ltd. (Australia), Singlera Genomics, Inc. (U.S.), Igenomix (Spain), Source Bioscience (U.K.), Pacgenomics (U.S.)

14 Company Profiles
(Overview, Products and Services, Financials, Strategy & Development)*
14.1 Top Product Manufacturers
14.1.1 Illumina, Inc.
14.1.2 Thermo Fisher Scientific Inc.
14.1.3 Agilent Technologies, Inc.
14.1.4 Perkinelmer, Inc.
14.1.5 Coopersurgical, Inc. (A Subsidiary of the Cooper Companies, Inc.)
14.1.6 ABBott Laboratories
14.1.7 Natera, Inc.
14.1.8 Rubicon Genomics (A Subsidiary of Takara Bio Usa Holdings, Inc.)
14.1.9 Oxford Gene Technology
14.1.10 Yikon Genomics
14.1.11 Scigene
14.2 Top Service Provider Companies
14.2.1 Beijing Genomics Institute
14.2.2 Good Start Genetics, Inc.
14.2.3 Invicta Genetics
14.2.4 Combimatrix Corporation
14.2.5 Genea Limited
14.2.6 Progenesis

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

15 Appendix
15.1 Insights of Industry Experts
15.2 Discussion Guide

List of Tables
Table 1 PGDS Product Launches, 2014-2017
Table 2 Global Incidence Rate Of Trisomy, 2014
Table 3 Incidence Rate Of Trisomy 21 In The U.S., 2014
Table 4 Procedural Costs For Pgd & Pgs Testing Across The World’S Major Countries/Regions, 2016
Table 5 Average Cost Of Pgs-Ivf Procedures In The U.S., 2016
Table 6 Public Healthcare Expenditure (% Of Annual Gdp): 2005 Vs. 2014
Table 7 Global PGDS Regulations, 2016
Table 8 Global PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 9 Pgs Procedure Type: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 10 Pgd Procedure Type: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 11 PGDS Market Size, By Technology, 2015–2022 (USD Million)
Table 12 Ngs Technology: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 13 Pcr Technology: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 14 Fish Technology: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 15 Cgh Technology: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 16 Snp Technology: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 17 PGDS Market Size, By Product & Service, 2015–2022 (USD Million)
Table 18 Reagents And Consumables: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 19 Instruments: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 20 Software And Services: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 21 PGDS Market Size, By Application, 2015–2022 (USD Million)
Table 22 Accuracy Rate Of Pgs Techniques For Aneuploidy
Table 23 Aneuploidy Application: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 24 Structural Chromosomal Abnormalities Application: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 25 Structural Chromosomal Abnormalities Application: PGDS Market, By Type, 2015–2022 (USD Million)
Table 26 Translocations Application: PGDS Structural Chromosomal Abnormalities Market Size, By Region, 2015–2022 (USD Million)
Table 27 Deletions Application: PGDS Structural Chromosomal Abnormalities Market Size, By Region, 2015–2022 (USD Million)
Table 28 Duplications Application: PGDS Structural Chromosomal Abnormalities Market Size, By Region, 2015–2022 (USD Million)
Table 29 Inversions Application: PGDS Structural Chromosomal Abnormalities Market Size, By Region, 2015–2022 (USD Million)
Table 30 Single Gene Disorders Application: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 31 X-Linked Disorders Application: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 32 Hla Typing Application: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 33 Gender Identification Application: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 34 PGDS Market Size, By End-User, 2015–2022 (USD Million)
Table 35 Maternity Centers & Fertility Clinics End-User: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 36 Hospitals, Diagnostic Labs, And Service Providers End-User: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 37 Research Laboratories & Academic Institutes End-User: PGDS Market Size, By Region, 2015–2022 (USD Million)
Table 38 Global PGDS Market Size, By Region, 2015-2022 (USD Million)
Table 39 North America: Major Pgd And Pgs Product Manufacturers And Service Providers
Table 40 North America: PGDS Market Size, By Country, 2015–2022 (USD Million)
Table 41 North America: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 42 North America: PGDS Market Size, By Technology, 2015–2022 (USD Million)
Table 43 North America: PGDS Market Size, By Product & Service, 2015–2022 (USD Million)
Table 44 North America: PGDS Market Size, By Application, 2015–2022 (USD Million)
Table 45 North America: PGDS Market Size For Structural Chromosomal Abnormalities, By Type, 2015–2022 (USD Million)
Table 46 North America: PGDS Market Size, By End-User, 2015–2022 (USD Million)
Table 47 U.S. Regulations For Infertility Treatment Procedures
Table 48 U.S.: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 49 Canadian Laws On Infertility Treatment Procedures (As Of 2016)
Table 50 Canada: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 51 Europe: Major Pgd And Pgs Product Manufacturers And Service Providers
Table 52 Europe: PGDS Market Size, By Country, 2015–2022 (USD Million)
Table 53 Europe: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 54 Europe: PGDS Market Size, By Technology, 2015–2022 (USD Million)
Table 55 Europe: PGDS Market Size, By Product & Service, 2015–2022 (USD Million)
Table 56 Europe: PGDS Market Size, By Application, 2015–2022 (USD Million)
Table 57 Europe: PGDS Market Size For Structural Chromosomal Abnormalities, By Type, 2015–2022 (USD Million)
Table 58 Europe: PGDS Market Size, By End-User, 2015–2022 (USD Million)
Table 59 Germany: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 60 U.K.: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 61 France: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 62 Roe: Regulations For Infertility Treatment (As Of 2016)
Table 63 Roe: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 64 Asia-Pacific: Major Pgd And Pgs Product Manufacturers And Service Providers
Table 65 Asia-Pacific: PGDS Market Size, By Country, 2015–2022 (USD Million)
Table 66 Asia-Pacific: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 67 Asia-Pacific: PGDS Market Size, By Technology, 2015–2022 (USD Million)
Table 68 Asia-Pacific: PGDS Market Size, By Product & Service, 2015–2022 (USD Million)
Table 69 Asia-Pacific: PGDS Market Size, By Application, 2015–2022 (USD Million)
Table 70 Asia-Pacific: PGDS Market Size For Structural Chromosomal Abnormalities, By Type, 2015–2022 (USD Million)
Table 71 Asia-Pacific: PGDS Market Size, By End-User, 2015–2022 (USD Million)
Table 72 China: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 73 Japan: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 74 India: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 75 Roapac: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 76 Row: Major Pgd And Pgs Product Manufacturers And Service Providers
Table 77 Row: PGDS Market Size, By Procedure Type, 2015–2022 (USD Million)
Table 78 Row: PGDS Market Size, By Technology, 2015–2022 (USD Million)
Table 79 Row: PGDS Market Size, By Product & Service, 2015–2022 (USD Million)
Table 80 Row: PGDS Market Size, By Application, 2015–2022 (USD Million)
Table 81 Row: PGDS Market Size For Structural Chromosomal Abnormalities, By Type, 2015–2022 (USD Million)
Table 82 Row: PGDS Market Size, By End-User, 2015–2022 (USD Million)
Table 83 Agreements, Collaborations, Partnerships, And Alliances 2014-2017
Table 84 Product Launches And Approvals, 2014–2017
Table 85 Acquisitions, 2014–2017
Table 86 Other Developments, 2014–2017

List of Figures
Figure 1 Global Preimplantation Genetic Diagnosis and Screening Market: Research Methodology Steps
Figure 2 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, and Region
Figure 3 Data Triangulation
Figure 4 Global Preimplantation Genetic Diagnosis and Screening Market Size, By Technology, 2017 vs 2022 (USD Million)
Figure 5 Global Preimplantation Genetic Testing Market Share, By Product & Service, 2017 vs 2022 (USD Million)
Figure 6 Global Preimplantation Genetic Diagnosis and Screening Market Size, By Procedure Type, 2017 vs 2022 (USD Million)
Figure 7 Global Preimplantation Genetic Testing Market Share, By Application, 2017 vs 2022 (USD Million)
Figure 8 Global Preimplantation Genetic Diagnosis and Screening Market Share, By End User, 2017 vs 2022 (USD Million)
Figure 9 Geographical Snapshot: Preimplantation Genetic Testing Market
Figure 10 Declining Fertility Rates & Technological Advancements in the Field of Genetic Analysis are Major Factors Driving Market Growth
Figure 11 NGS Accounted for the Largest Market Share in 2016
Figure 12 Aneuploidy Segment Dominates the Preimplantation Genetic Diagnosis and Screening Market
Figure 13 Reagents & Consumables Segment Will Continue to Dominate the Market in 2022
Figure 14 Asia-Pacific to Register the Highest CAGR During the Forecast Period
Figure 15 Drivers, Restraints, Opportunities, and Challenges
Figure 16 Global Female Fertility Rate (2004-2015)
Figure 17 U.S. Global Health Funding: Family Planning/Reproductive Health (2006-2016)
Figure 18 Value Chain Analysis: Preimplantation Genetic Diagnosis and Screening Industry (2016)
Figure 19 Porter’s Five Forces Analysis: Preimplantation Genetic Diagnosis and Screening Market (2016)
Figure 20 Federal Regulations in the U.S. on Genetic Testing (2016)
Figure 21 Preimplantation Genetic Diagnosis and Screening Market, By Procedure Type, 2017 vs 2022 (USD Million)
Figure 22 Preimplantation Genetic Testing Market Size, By Technology, 2017 vs 2022 (USD Million)
Figure 23 Preimplantation Genetic Diagnosis and Screening Market, By Products & Services, 2017 vs 2022 (USD Million)
Figure 24 Preimplantation Genetic Diagnosis and Screening Market Size, By Application, 2017 vs 2022 (USD Million)
Figure 25 Preimplantation Genetic Testing Market Size, By End User, 2017 vs 2022 (USD Million)
Figure 26 Preimplantation Genetic Diagnosis and Screening Market, By Region
Figure 27 Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 28 North America: Preimplantation Genetic Diagnosis and Screening Market Snapshot
Figure 29 Europe: Preimplantation Genetic Testing Market Snapshot
Figure 30 Asia-Pacific: Preimplantation Genetic Diagnosis and Screening Market Snapshot
Figure 31 RoW: Preimplantation Genetic Testing Market Snapshot
Figure 32 Global Preimplantation Genetic Diagnosis and Screening Market Ranking: Top 5 Players (2016)
Figure 33 Agreements, Partnerships, Collaborations, and Alliances-Majorly Adopted Growth Strategy By Market Players From 2014 to 2017
Figure 34 Global Preimplantation Genetic Diagnosis and Screening Competitive Leadership Mapping, 2017
Figure 35 Illumina, Inc.: Company Snapshot (2016)
Figure 36 Thermo Fisher Scientific Inc.: Company Snapshot (2016)
Figure 37 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 38 Perkinelmer, Inc.: Company Snapshot (2016)
Figure 39 The Cooper Companies Inc.: Company Snapshot (2016)
Figure 40 ABBott Laboratories: Company Snapshot (2016)
Figure 41 Natera, Inc.: Company Snapshot (2016)
Figure 42 Combimatrix Corporation: Company Snapshot (2016)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ABBott Laboratories
  • Genea Limited
  • Illumina, Inc.
  • Natera, Inc.
  • Perkinelmer, Inc.
  • Scigene
  • MORE

The global preimplantation genetic testing market is expected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%. The growth of this market is majorly driven by the rising rate of infertility across the globe, increasing number of fertility clinics worldwide, public-private investments in the field of preimplantation genetic testing, technological advancements in the field of genetic analysis, and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.

The report analyzes the global preimplantation genetic testing market by technology, product & service, procedure type, application, end user, and region. Based on technology, the next-generation sequencing (NGS) segment accounted for the largest share owing to the advantages offered by NGS such as reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes, and reduction in human errors due to increased automation.

By product & service, the reagents & consumables segment accounted for the largest market share owing to expanding application horizons of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders). Based on procedure type, the genetic screening segment accounted for the largest share due to continuous decline in female fertility (due to rising maternal age) and benefits offered by PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

In terms of application, the aneuploidy segment held the largest share in 2016. Factors such as increasing maternal age and rising incidence of aneuploidy have led to the growth of this segment. Among end users, the maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market due to factors such as increasing number of fertility centers and the high treatment success rate at such centers.

This report covers the preimplantation genetic testing market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global preimplantation genetic testing market in 2016, followed by Europe. The large share in the North American region is mainly attributed to the rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, and the ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS). The Asia-Pacific region is expected to register the highest growth rate during the forecast period, due to the growing focus of players on emerging markets and improvements in healthcare infrastructure in these regions.

The high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the key factors restraining the growth of this market.

Illumina, Inc. (U.S.) dominates the market through its wide range of technologically advanced and innovative preimplantation genetic testing products. The company adopts the strategy of agreements and partnerships to maintain its leadership position in the market.

Other prominent players in the preimplantation genetic testing market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others

Note: Product cover images may vary from those shown
5 of 5
  • ABBott Laboratories
  • Agilent Technologies, Inc.
  • Beijing Genomics Institute
  • Combimatrix Corporation
  • Coopersurgical, Inc. (A Subsidiary of the Cooper Companies, Inc.)
  • Genea Limited
  • Good Start Genetics, Inc.
  • Illumina, Inc.
  • Invicta Genetics
  • Natera, Inc.
  • Oxford Gene Technology
  • Perkinelmer, Inc.
  • Progenesis
  • Rubicon Genomics (A Subsidiary of Takara Bio Usa Holdings, Inc.)
  • Scigene
  • Thermo Fisher Scientific Inc.
  • Yikon Genomics
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll